Development and validation of quality indicators for lupus nephritis, based on the 2025 EULAR recommendations: adherence trends and impact on clinical outcomes

Annals of the Rheumatic Diseases · Published 2026-07-01 · DOI 10.1016/j.ard.2026.05.030

Authors (31)

Εda Otman Akat, Myrto Kostopoulou, Spyridon Katechis, Konstantinos Drougkas, Katerina Chavatza, Andreas Kronbichler, Bernardo A Pons-Estel, Brad H Rovin, György Nagy, Jinoos Yazdany, Lucy Marie Carter, Luis F Quintana, Mandana Nikpour, Manuel Praga, Manuel F Ugarte-Gil, Maria Dall’Era, Maria Trachana, Marta Mosca, Michael M Ward, Ming-Hui Zhao, Murat Inanc, Nobuyuki Yajima, Sandra Navarra, Sophia Lionaki, Tamer A Gheita, Vladimir Tesar, Zahir Amoura, Zahi Touma, George Bertsias, Antonis Fanouriakis, Dimitrios T Boumpas

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Akat, Ε., Kostopoulou, M., Katechis, S., et al. (2026). Development and validation of quality indicators for lupus nephritis, based on the 2025 EULAR recommendations: adherence trends and impact on clinical outcomes. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2026.05.030

Related articles

• Thresholds for efficacy outcomes in psoriatic arthritis vary according to baseline disease activity but not according to prior tumour necrosis factor inhibitor treatment · Annals of the Rheumatic Diseases · 2026 · Same journal
• Response to correspondence on ‘Final validation of the hierarchical framework for outcomes in axial spondyloarthritis: longitudinal determinants of health-related quality of life’ · Annals of the Rheumatic Diseases · 2026 · Same journal
• Mitochondrial-impaired ductal epithelium fuels TLS formation in Sjögren’s disease · Annals of the Rheumatic Diseases · 2026 · Same journal
• Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis · Annals of the Rheumatic Diseases · 2026 · Same journal
• Influence of national socioeconomic status on treatment retention and disease activity in psoriatic arthritis and axial spondyloarthritis: evidence over 2 years in 13 European countries · Annals of the Rheumatic Diseases · 2026 · Same journal
• Remission of refractory lupus nephritis is temporally associated with antitumour therapy, including durvalumab for endometrial carcinoma · Annals of the Rheumatic Diseases · 2026 · Same journal
• Mapping inequalities in rheumatology care in Europe: the first edition of the EULAR RheumaFacts project · Annals of the Rheumatic Diseases · 2026 · Same journal
• Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis—a case series · Annals of the Rheumatic Diseases · 2026 · Same journal
• Symmetrical dimethylarginine as the central antigenic determinant of anti-Smith autoantibodies in systemic lupus erythematosus · Annals of the Rheumatic Diseases · 2026 · Same journal
• A novel STAT4 gain-of-function variant defines a monogenic form of juvenile-onset systemic lupus erythematosus · Annals of the Rheumatic Diseases · 2026 · Same journal